Background: Tissue factor (TF) is the main initiator of coagulation in vivo. Recently, however, a role for TF as a cell receptor involved in signal transduction has been suggested. The aim of the present study was to assess whether activated factor VII (FVIIa) binding to TF could induce smooth muscle cell (SMC) proliferation and to clarify the possible intracellular mechanism(s) responsible for this proliferation.

Methods And Results: Cell proliferation was induced by FVIIa in a dose-dependent manner, as assessed by [3H]thymidine incorporation and direct cell counting, whereas no response was observed with active site-inhibited FVIIa (FVIIai), which is identical to FVIIa but is devoid of enzymatic activity. Similarly, no proliferation was observed when binding of FVIIa to TF was prevented by the monoclonal anti-TF antibody AP-1. Activation of the p44/42 mitogen-activated protein (MAP) kinase (extracellular signal-regulated kinases 1 and 2 [ERK 1/2]) pathway on binding of FVIIa to TF was demonstrated by transient ERK phosphorylation in Western blots and by suppression of proliferation with the specific MEK (MAP kinase/ERK kinase) inhibitor UO126. ERK phosphorylation was not observed with FVIIai or when cells were pretreated with AP-1.

Conclusions: These data indicate a specific effect by which binding of FVIIa to TF on the surface of SMCs induces proliferation via a coagulation-independent mechanism and possibly indicate a new link between coagulation, inflammation, and atherosclerosis.

Download full-text PDF

Source
http://dx.doi.org/10.1161/01.CIR.0000129312.43547.08DOI Listing

Publication Analysis

Top Keywords

binding fviia
12
tissue factor
8
activated factor
8
factor vii
8
smooth muscle
8
muscle cell
8
cell proliferation
8
extracellular signal-regulated
8
erk phosphorylation
8
fviia
7

Similar Publications

Formation of the extrinsic complex (EC) on cell surfaces is the event that triggers the coagulation cascade. Tissue factor (TF) and factor VIIa (FVIIa) form the EC together with factor X (FX) on phosphatidylserine-containing membranes, leading to FX activation by TF:FVIIa. This lipid dependence has made experimental characterization of the EC structure challenging.

View Article and Find Full Text PDF
Article Synopsis
  • - Neutrophils can release their DNA and contents to fight infections, but this can impact blood coagulation through a protein called TFPI, which is affected by an enzyme (PAD4) that alters (citrullinates) it, reducing its ability to prevent blood clotting.
  • - The study aimed to explore how this citrullination affects TFPI's performance in inhibiting key components of blood coagulation, specifically FXa and the FVIIa/tissue factor complex, using various laboratory techniques.
  • - Results showed that while citrullination severely weakened TFPI's ability to inhibit FXa, it still had some effect on FVIIa/tissue factor activity with the help of another protein (
View Article and Find Full Text PDF

Back to basics: the coagulation pathway.

Blood Res

October 2024

Daisy Hill Hospital, 5 Hospital Road, Newry, BT35 8DR, UK.

The classic coagulation cascade model of intrinsic and extrinsic coagulation pathways, i.e. contact activation pathway and tissue factor pathway, has been widely modified.

View Article and Find Full Text PDF

The intricate allostery in factor VIIa: triggering the trigger.

J Thromb Haemost

January 2025

Section for Metabolic Receptology, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark. Electronic address:

Article Synopsis
  • * Researchers found out that when FVIIa and TF work together, they change shape and function in complex ways that help the blood clotting process.
  • * Scientists are learning how to control FVIIa activity better, which could help in the future to improve treatments for blood clotting issues.
View Article and Find Full Text PDF

Concizumab improves clot formation in hemophilia A under flow.

J Thromb Haemost

September 2024

Department of Bioengineering, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, USA; Department of Pediatrics, Section of Hematology, Oncology, and Bone Marrow Transplant, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA; Hemophilia and Thrombosis Center, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA. Electronic address:

Background: Inhibition of tissue factor pathway inhibitor (TFPI) is an emerging therapeutic strategy for treatment of hemophilia. Concizumab is a monoclonal antibody that binds TFPI and blocks its inhibition of factor (F)Xa thereby extending the initiation of coagulation and compensating for lack of FVIII or FIX.

Objectives: The objective of this in vitro study was to evaluate how concizumab affects clot formation in hemophilia A under flow.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!